MeiraGTx Prices $100M Offering at $9 to Fund Gene Therapy Launches
MeiraGTx priced an underwritten offering of 11.11 million ordinary shares at $9 per share to raise roughly $100 million gross. Net proceeds plus cash will fund operating expenses, capital expenditures and potential commercial launches of bota-vec and AAV-hAQP1 into H2 2028.
1. Offering Details
MeiraGTx has priced an underwritten offering of 11,111,111 ordinary shares at $9.00 per share, targeting gross proceeds of approximately $100 million before underwriting discounts and commissions. The offering, expected to close on April 17, 2026, is led by BofA Securities and Goldman Sachs & Co. LLC as joint book-running managers, with Raymond James as co-manager.
2. Use of Proceeds
The company expects that net proceeds from the offering, together with existing cash and cash equivalents, will be sufficient to fund operating expenses, capital expenditures and potential commercial launches of bota-vec for X-linked retinitis pigmentosa and AAV-hAQP1 for radiation-induced xerostomia into the second half of 2028.
3. Registration and Closing Conditions
The shares are being offered under a Form S-3 shelf registration statement declared effective in December 2023, with final terms to be disclosed in a prospectus supplement. Closing remains subject to customary conditions and finalization of offering expenses.